The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
ORGANIZATION
JPMA Exec Urges Immediate Action on Inflation Pressures as Budget Talks Loom
Japan Pharmaceutical Manufacturers Association (JPMA) Director General Kenshi Kinoshita on November 13 renewed the trade group’s call for urgent measures to address inflationary pressures facing the pharmaceutical industry, saying that countermeasures “can no longer be delayed” as year-end budget debates…
To read the full story
Related Article
- JPMA Exec Renews Call for Simpler Drug Pricing System
December 19, 2025
- JPMA Chief Renews Call for Reflecting Inflation and Wage Hikes in Drug Pricing
October 17, 2025
ORGANIZATION
- FY2026 Reform Tilted toward Price Cuts despite Spillover Scrap: FPMAJ Chair
January 6, 2026
- Pfizer Japan President Igarashi Takes Helm as PhRMA Japan Chair
January 6, 2026
- Industry Leaders Call for Proper Rewards for Innovation in New Year Messages
January 5, 2026
- Generic Use Rate Rises Further to 89.5% in July-September: JGA
January 5, 2026
- Trade Groups Hail Spillover Abolition, but Urge Further Overhauls
December 26, 2025
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…